Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study

• DOI: 10.1007/s11060-016-2275-x
• Publication Date: 2016-09-21T07:21:21Z
• Authors: Pierre Chabot; Te-Chun Hsia; Jeong-Seon Ryu; Vera Gorbunova; Cristobal Belda-I...; David Ball; Ebenezer Kio; Minesh Mehta; Katherine Papp; Qin Qin; Jane Qian; Kyle D. Holen; Vince Giranda; John H. Suh
• Keywords: Adult; Male; Cancer Research; Lung Neoplasms; Clinical Neurology; 610; Antineoplastic Agents; 03 medical and health sciences; 0302 clinical medicine; Non-small cell lung cancer; Double-Blind Method; Carcinoma, Non-Small-Cell Lung; 616; Humans; Longitudinal Studies; Aged; Aged, 80 and over; Brain Neoplasms; Veliparib; Brain metastases; Middle Aged; Whole-brain radiation therapy; 3. Good health; PARP inhibitor; Treatment Outcome; Oncology; Neurology; Clinical Study; Benzimidazoles; Female; Randomized clinical trial; Cranial Irradiation

Veliparib is a potent, orally bioavailable, poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor that crosses the blood-brain barrier and has been shown to potentiate the effects of radiation in preclinical and early clinical studies. This phase 2, randomized, global study evaluated the efficacy and safety of veliparib in combination with whole-brain radiation therapy (WBRT) in patients with brain metastases from non-small cell lung cancer (NSCLC). Three-hundred and seven patients with brain metastases from NSCLC were randomized 1:1:1 to WBRT (30 Gy in 10 fractions) plus 50 mg veliparib twice daily (BID; n = 103), 200 mg veliparib BID (n = 102), or placebo BID (n = 102). Treatment began within 28 days of diagnosis. Tumor response and safety were assessed; the primary endpoint was overall survival (OS). Patients who received ≥1 dose of treatment were included in the safety analysis. All randomized patients were included in the efficacy endpoint analyses. Patient characteristics were well balanced between treatment arms. Median OS was 185 days for patients treated with WBRT plus placebo and 209 days for WBRT plus veliparib (50 or 200 mg). No statistically significant differences in OS, intracranial response rate, and time to clinical or radiographic progression between any of the treatment arms were noted. No differences were observed in adverse events (all grades) across treatment arms; nausea, fatigue, alopecia, and headache were the most commonly reported. No new safety signals were identified for veliparib. A significant unmet need for therapies that improve the outcomes of patients with brain metastases from NSCLC remains.